In vitro and in vivo studies of a novel selective cMET inhibitor, SU11274, tested alone or in combination with bortezomib, lenalidomide and dexamethasone, suggest that the HGF/cMET pathway may be envisaged as a new therapeutic target for relapsed and refractory MM patients [28]. The gene discussed is MET; the disease is Miyoshi myopathy.